Modified Penetratin Peptides for Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular drug delivery methods face challenges such as low bioavailability and poor patient compliance due to the physiological barriers of the eye, with existing absorption enhancers often causing irritation and systemic side effects.
Innovation Solution
Development of artificially modified cell-penetrating peptide (CPP) derivatives with enhanced hydrophobicity, designed to improve penetration into ocular tissues while maintaining biosafety, allowing for non-traumatic delivery of drugs through eye drops to the posterior segment of the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If small molecule absorption enhancers (such as ethanol, dimethyl sulfoxide) are used to improve drug absorption, then the penetration ability is enhanced, but ocular irritation and toxicity occur
Solution Approach 1:
The patent modifies the amino acid sequence of penetratin by substituting hydrophilic residues (Serine, Threonine, Glutamine, Asparagine) with hydrophobic residues (Alanine, Valine, Leucine, Isoleucine, Phenylalanine, Tryptophan, Methionine) to optimize the balance between penetration efficiency and ocular safety. This parameter change in molecular hydrophobicity allows the peptide to enhance drug absorption while reducing the irritation caused by traditional small molecule enhancers
Solution Approach 2:
The patent creates composite structures by conjugating the modified penetratin peptide with various drugs through chemical linkers. This composite approach combines the penetration-enhancing properties of the peptide with the therapeutic effects of different drugs, achieving both improved absorption and reduced side effects compared to using small molecule enhancers alone
2Productivity
If intraocular injection is used to achieve high bioavailability, then drug delivery efficiency is improved, but patient compliance deteriorates due to traumatic administration
Solution Approach 1:
The modified penetratin peptide acts as an intermediary substance that enables non-invasive drug delivery. When conjugated to drugs and administered as eye drops, the peptide mediates the transport of drugs across ocular barriers (cornea, conjunctiva) to reach intraocular tissues, achieving high bioavailability without the need for invasive injections
Solution Approach 2:
The patent replaces the mechanical injection system with a chemical-biological system. Instead of using physical force to inject drugs directly into the eye, the modified penetratin peptide uses its cell-penetrating properties to facilitate drug absorption through ocular membranes, substituting a traumatic mechanical process with a non-invasive chemical-biological mechanism
3Productivity
If systemic administration is used to treat ocular diseases, then drug availability is improved, but systemic side effects increase due to large doses required
Solution Approach 1:
The modified penetratin peptide serves as a targeted delivery mediator that directs drugs specifically to ocular tissues. When conjugated to drugs and administered systemically or topically, the peptide mediates selective accumulation of the drug in the eye, achieving high local concentration with low systemic exposure, thereby improving drug availability while minimizing systemic side effects
Solution Approach 2:
The patent achieves local quality by concentrating the drug-penetratin conjugate specifically in ocular tissues. The modified penetratin peptide exhibits selective affinity for ocular barriers and tissues, enabling the drug to accumulate locally at high concentrations while maintaining low systemic levels, thus providing effective ocular treatment with reduced systemic side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified penetratin derivatives significantly enhance ocular bioavailability and absorption of drugs, reducing systemic side effects and improving patient compliance by effectively overcoming ocular barriers, with enhanced hydrophobicity correlating to increased penetrating ability.
Implementation Method 1
Development of artificially modified cell-penetrating peptide (CPP) derivatives with enhanced hydrophobicity, designed to improve penetration into ocular tissues
Data Source
AI summary
The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.